Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany.
Arch Pharm (Weinheim). 2012 Jul;345(7):557-64. doi: 10.1002/ardp.201100474. Epub 2012 Mar 30.
Cationic [bis(1,3-diethyl-4,5-diarylimidazol-2-ylidene)]Au(I) bromide complexes have demonstrated considerable potential as new antitumor agents. In order to investigate whether the gold is crucial for the antitumor activity, the imidazole ligands were connected by a methylene bridge. Biological evaluation revealed that bis[1,3-diethyl-4,5-diarylimidazol-2-ylidene]methane compounds exhibited growth inhibition effects against mammary (MCF-7 and MDA-MB 231) and colon (HT-29) carcinoma cell lines. In comparison with gold complexes, the methylene derivatives showed drastically reduced cell growth inhibitory properties. However, the growth of bacteria was significantly inhibited by bis[1,3-diethyl-4,5-bis(4-methoxyphenyl)imidazol-2-ylidene]methane dibromide (4) and opens a new application of this compound type.
阳离子[双(1,3-二乙基-4,5-二芳基咪唑-2-亚基)]金(I)溴化物复合物已被证明具有作为新型抗肿瘤剂的巨大潜力。为了研究金是否对抗肿瘤活性至关重要,将咪唑配体通过亚甲基桥连接。生物评价表明,双[1,3-二乙基-4,5-二芳基咪唑-2-亚基]甲烷化合物对乳腺(MCF-7 和 MDA-MB 231)和结肠(HT-29)癌细胞系表现出生长抑制作用。与金复合物相比,亚甲基衍生物显示出明显降低的细胞生长抑制特性。然而,双[1,3-二乙基-4,5-双(4-甲氧基苯基)咪唑-2-亚基]甲烷二溴化物(4)显著抑制了细菌的生长,为这种化合物类型开辟了新的应用。